Currently, there are 155.78M common shares owned by the public and among those 140.52M shares have been available to trade.
The company’s stock has a 5-day price change of 6.21% and 34.08% over the past three months. TGTX shares are trading -1.20% year to date (YTD), with the 12-month market performance up to 72.71% higher. It has a 12-month low price of $12.84 and touched a high of $36.84 over the same period. TGTX has an average intraday trading volume of 2.95 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.81%, -4.53%, and 32.56% respectively.
Institutional ownership of TG Therapeutics Inc (NASDAQ: TGTX) shares accounts for 65.85% of the company’s 155.78M shares outstanding.
It has a market capitalization of $4.63B and a beta (3y monthly) value of 2.27. The earnings-per-share (ttm) stands at -$0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.43% over the week and 5.79% over the month.
Analysts forecast that TG Therapeutics Inc (TGTX) will achieve an EPS of 0.08 for the current quarter, 0.14 for the next quarter and 0.93 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.06 while analysts give the company a high EPS estimate of 0.06. Comparatively, EPS for the current quarter was -0.1 a year ago. Earnings per share for the fiscal year are expected to increase by 14.81%, and 871.37% over the next financial year.
Looking at the support for the TGTX, a number of firms have released research notes about the stock. TD Cowen stated their Buy rating for the stock in a research note on October 29, 2024, with the firm’s price target at $50. Goldman coverage for the TG Therapeutics Inc (TGTX) stock in a research note released on August 02, 2023 offered a Neutral rating with a price target of $12. Jefferies was of a view on June 26, 2023 that the stock is Buy, while BofA Securities gave the stock Underperform rating on May 20, 2022, issuing a price target of $5. B. Riley Securities on their part issued Buy rating on February 23, 2022.
